

**IN THE CLAIMS:**

The following is a listing of the claims as currently amended:

1. (Original) A method for the treatment of glycine-extended gastrin-17-dependent gastrointestinal tumors, comprising administering to a mammal a therapeutically effective amount of an anti-G17 immunogenic composition.
2. (Currently amended) The method of claim 1, wherein the immunogen immunogenic composition induces anti-G17 antibodies of an effective titer in the immunized animal which bind and neutralize amidated and glycine-extended gastrin-17.
3. (Currently amended) The method of claim 1, wherein the gastrointestinal tumors contain gastrin/choleystochinin gastrin/cholecystokinin B (CCK-B) receptors.
4. (Original) The method of claim 1, wherein the gastrointestinal tumors are colorectal adenocarcinomas.
5. (Original) The method of claim 1, wherein the mammal is a human.